Infringement case now only focused on ‘793 patent, previously found to be invalid by PTAB in IPR Federal Circuit expected to hear appeal of PTAB decision in late 4th quarter 2023 to early 2024 If PTAB decision affirmed, Liquidia will request final regulatory approval for YUTREPIA™ (treprostinil)

Liquidia exclusively licenses North American rights to L606, an inhaled formulation of treprostinil administered twice-daily with a short duration, next-generation nebulizer Liquidia funds $10 million upfront payment from finance agreement with HealthCare Royalty Pharmosa to receive up to $215

MORRISVILLE, N.C. , May 31, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that Mr. Roger Jeffs , Chief Executive Officer, and Mr. Michael Kaseta , Chief Financial Officer, will provide an update on the Company's business during a fireside chat at the

MORRISVILLE, N.C. , May 19, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the Company will present data related to the investigational use of YUTREPIA™ (treprostinil) inhalation powder at the 2023 American Thoracic Society (ATS)

MORRISVILLE, N.C. , May 04, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) ( Liquidia or the Company) today reported financial results for the first quarter ended March 31, 2023 . The Company will host a webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate

MORRISVILLE, N.C. , May 02, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta , Chief Financial Officer, will provide an update on the company's business during a fireside chat at the BofA Securities 2023 Health Care Conference in Las Vegas, Nevada

MORRISVILLE, N.C. , April 27, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its first quarter 2023 financial results on Thursday, May 4, 2023 . The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a

MORRISVILLE, N.C. , April 11, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta , Chief Financial Officer, will provide an overview and update on the company's business during a fireside chat session at the 22nd Annual Needham Virtual Healthcare

New agreement supersedes the collaboration agreement entered in 2012 GSK retains non-exclusive right to use PRINT for pre-clinical research for inhaled delivery Liquidia can apply PRINT to any inhaled application other than identified GSK proprietary molecules MORRISVILLE, N.C.

Clarified path to potential launch YUTREPIA upon resolution of litigation in late-2023 to mid-2024 Fortified financial position through 2024 Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C. , March 16, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the